Episode 80
Biotech Hangout
00:00
The Impact of Weight Loss Drugs on Reimbursement and Cardiovascular Risk
The chapter explores the recent approval in the weight loss space by wagovie and its implications on reimbursement by insurers and the government. The speakers discuss the challenges in achieving reimbursement and the potential influence of a landmark cardiovascular outcome study. They also highlight the growth of the private pay market and its impact on consumers self-paying for weight loss drugs.
Transcript
Play full episode
